#1 Clinical Trials Search in Europe

Pembrolizumab

Pembrolizumab, also known by its brand name Keytruda, is an immunotherapy drug being studied in various clinical trials for different types of cancer. This article explores recent clinical trials investigating the use of pembrolizumab in treating conditions such as melanoma, non-small cell lung cancer, biliary tract cancer, and other solid tumors. We’ll look at how the drug works, its potential benefits, and what researchers hope to learn from these studies.

Table of Contents

What is Pembrolizumab?

Pembrolizumab is a type of cancer treatment known as immunotherapy. It’s also referred to by its brand name Keytruda[1]. This medication is designed to help your body’s own immune system fight cancer cells. Pembrolizumab is a monoclonal antibody, which is a type of protein made in a laboratory that can bind to specific targets in the body, such as cancer cells[2].

How Does Pembrolizumab Work?

Pembrolizumab works by targeting a protein called PD-1 (programmed death 1) that is found on certain immune cells called T cells. Normally, PD-1 acts as a type of “off switch” that helps prevent T cells from attacking other cells in the body. Some cancer cells can take advantage of this by expressing PD-L1, which binds to PD-1 and turns off the T cells, allowing the cancer to hide from the immune system.

Pembrolizumab blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2). By doing this, it allows the T cells to remain active and detect and attack cancer cells[1]. In simpler terms, pembrolizumab helps “unmask” the cancer cells so that your immune system can recognize and destroy them.

What Types of Cancers Does Pembrolizumab Treat?

Pembrolizumab has shown effectiveness in treating various types of cancers. Based on the clinical trials information provided, it is being studied or used to treat:

  • Melanoma: A type of skin cancer[1]
  • Non-small cell lung cancer (NSCLC)[3]
  • Head and neck squamous cell carcinoma: Cancers that start in the mouth, nose, or throat[4]
  • Ovarian clear cell carcinoma: A rare type of ovarian cancer[5]
  • Breast cancer: Specifically, hormone receptor-positive, HER2-negative breast cancer[2]
  • Thymic carcinoma: A rare cancer of the thymus gland[6]

It’s important to note that research is ongoing, and pembrolizumab may be effective for other types of cancers as well.

How is Pembrolizumab Administered?

Pembrolizumab is typically given as an intravenous (IV) infusion. This means it’s administered directly into your bloodstream through a vein. The usual dose is 200 mg, given once every three weeks[1]. Each treatment cycle is generally 21 days long. The infusion usually takes about 30 minutes to complete.

The duration of treatment can vary depending on how well the cancer responds and how well you tolerate the medication. In some cases, treatment may continue for up to two years if the cancer is responding well and side effects are manageable[3].

Pembrolizumab in Combination Therapies

Researchers are exploring the use of pembrolizumab in combination with other cancer treatments to potentially enhance its effectiveness. Some combinations being studied include:

  • Pembrolizumab with lenvatinib: This combination is being studied for various cancers, including ovarian clear cell carcinoma and thymic carcinoma[5].
  • Pembrolizumab with radiation therapy: This combination is being investigated for breast cancer[2].
  • Pembrolizumab with chemotherapy: This combination is being studied for lung cancer[3].
  • Pembrolizumab with other targeted therapies: For example, combination with crizotinib for certain types of lung cancer[7].

Potential Side Effects

Like all medications, pembrolizumab can cause side effects. Because it works by stimulating your immune system, many of the side effects are related to an overactive immune response. Some potential side effects include:

  • Fatigue
  • Skin rash or itching
  • Nausea or diarrhea
  • Joint pain
  • Decreased appetite
  • Fever

More serious side effects can occur, though they are less common. These may include inflammation in various parts of the body, such as the lungs (pneumonitis), intestines (colitis), or hormone-producing glands (endocrinopathies)[7]. It’s important to report any new symptoms to your healthcare team promptly.

Ongoing Research and Future Directions

Research on pembrolizumab is ongoing, with many clinical trials exploring its use in different types of cancers and in combination with other treatments. Some areas of current research include:

  • Identifying biomarkers to predict which patients will respond best to pembrolizumab. For example, some studies are looking at the levels of a protein called PD-L1 in tumor cells[7].
  • Investigating the effectiveness of pembrolizumab in cancers that have spread to the brain or spinal cord (leptomeningeal metastases)[8].
  • Exploring the use of pembrolizumab earlier in the course of cancer treatment, including as a first-line therapy for some cancers[1].
  • Studying how pembrolizumab might be used to treat cancers that have become resistant to other forms of treatment[4].

These ongoing studies aim to improve our understanding of how pembrolizumab works and how it can be used most effectively to help patients with various types of cancer.

Aspect Details
Drug Name Pembrolizumab (Keytruda)
Drug Type Immunotherapy (PD-1 inhibitor)
Administration Intravenous infusion, typically every 3 weeks
Common Dose 200 mg for adults (may vary in some trials)
Cancer Types Studied Melanoma, Non-small cell lung cancer, Biliary tract cancer, Ovarian squamous cell carcinoma, Urothelial bladder carcinoma, Merkel cell carcinoma, Other advanced solid tumors
Key Outcomes Measured Objective response rate, Progression-free survival, Overall survival, Safety and tolerability
Trial Phases Phase 1, 2, and 3 studies represented
Combination Therapies Some trials studying pembrolizumab alone, others in combination with other drugs
Special Considerations Biosimilar studies, neoadjuvant use, pharmacokinetic assessments

FAQ

  • What is pembrolizumab and how does it work? Pembrolizumab is an immunotherapy drug that helps the body's immune system recognize and fight cancer cells. It works by blocking a protein called PD-1, which normally prevents T cells (a type of immune cell) from attacking other cells in the body. By blocking PD-1, pembrolizumab allows T cells to better identify and destroy cancer cells.
  • What types of cancer is pembrolizumab being studied for? Based on the clinical trials mentioned, pembrolizumab is being studied for various types of cancer, including melanoma, non-small cell lung cancer (NSCLC), biliary tract cancer, ovarian squamous cell carcinoma, urothelial bladder carcinoma, Merkel cell carcinoma, and other advanced solid tumors.
  • How is pembrolizumab administered in these clinical trials? In most of the trials mentioned, pembrolizumab is administered intravenously (through a vein) every 3 weeks. The typical dose for adults is 200 mg, although some trials may use different dosing schedules or amounts.
  • What are the main goals of these clinical trials? The main goals of these trials include assessing the safety and effectiveness of pembrolizumab, either alone or in combination with other treatments. Researchers are looking at factors such as tumor response rates, progression-free survival, overall survival, and potential side effects.
  • Are there any potential side effects of pembrolizumab? Like all medications, pembrolizumab can cause side effects. In these trials, researchers are closely monitoring for adverse events. Common side effects of immunotherapy drugs like pembrolizumab can include fatigue, skin reactions, and immune-related side effects. The specific trials are designed to further evaluate the safety profile of the drug in different patient populations.

Ongoing Clinical Trials on Pembrolizumab

  • A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark France Germany Greece +6

  • A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +6

  • Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of intraperitoneal paclitaxel combined with systemic therapy versus systemic therapy alone for patients with gastric cancer and peritoneal metastases

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy The Netherlands Norway Sweden

  • Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Poland Spain

  • Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Finland France Germany Greece +8

  • Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Greece Hungary Poland Romania Spain

Glossary

  • Pembrolizumab: An immunotherapy drug that works by blocking the PD-1 protein, helping the immune system to better recognize and attack cancer cells.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • PD-1: A protein on T cells that normally helps prevent them from attacking other cells in the body. Some cancer cells can use PD-1 to avoid being attacked by the immune system.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Biosimilar: A biological product that is highly similar to and has no clinically meaningful differences from an existing approved reference product.

References

  1. https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-advanced-melanoma-with-braf-v600e-k-mutation/
  2. https://clinicaltrials.gov/study/NCT03051672
  3. https://clinicaltrials.gov/study/NCT04166487
  4. https://clinicaltrials.gov/study/NCT04150900
  5. https://clinicaltrials.gov/study/NCT05296512
  6. https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-lenvatinib-for-patients-with-pre-treated-thymic-carcinoma-and-b3-thymoma/
  7. https://clinicaltrials.gov/study/NCT02511184
  8. https://clinicaltrials.gov/study/NCT04729348